NeoImmuneTech Collaborates with Australian Imugene on Research: "Combination of Immuno-Oncology and CAR-T"

Immune Checkpoint Inhibitor 'NT-I7' Material Transfer Agreement Signed

NeoImmuneTech announced on the 12th that it has signed a strategic research collaboration agreement with Imugene, an Australian listed immuno-oncology development company.

NeoImmuneTech CI.
Photo by NeoImmuneTech

Under this agreement, NeoImmuneTech will provide its immuno-oncology candidate NT-I7 to Imugene, which will conduct research combining it with the chimeric antigen receptor (CAR)-T therapy 'azer-cel'.

Imugene, an immuno-oncology development company, is developing clinical-stage immunotherapies that activate the immune system of cancer patients. Imugene's pipeline includes ▲ the CAR-T therapy candidate azer-cel ▲ oncolytic virus therapy (CF33) ▲ immune therapy B-cell vaccine candidates, among others. Recently, 'VAXINIA', one of the CF33 candidates, was selected for expedited review by the U.S. Food and Drug Administration (FDA).

The combination therapy candidate azer-cel is an allogeneic CD19 CAR-T developed by Imugene based on extensive clinical data. According to the company, it has demonstrated safety in indications such as lymphoma and hematologic cancers so far.

Leslie Chong, CEO of Imugene, said, "We are very pleased to collaborate with NeoImmuneTech to enhance the potential efficacy of azer-cel."

Yang Se-hwan, CEO of NeoImmuneTech, stated, "NT-I7 has shown promising results across multiple indications in immuno-oncology and infectious diseases. Through this research collaboration with Imugene, a leader in the allogeneic cell therapy market, we expect to significantly expand the potential of NT-I7 and accelerate its commercialization timeline."

A NeoImmuneTech representative said, "Since mid-this year, we have started investment in the supply of NT-I7 and have signed material supply agreements with a total of six companies including this contract. We aim to continue expanding supply to numerous global biotech companies so that T-cell enhancers become a platform in the immuno-oncology field, and we hope that our global partners’ therapies will become more competitive through NT-I7."